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Background: Cancer is the leading cause of deaths in the world. A widening disparity in cancer burden has emerged
between high income and low-middle income countries. Closing this cancer divide is an ethical imperative but there is
a dearth of data on cancer services from developing countries.
Methods: This was a multi-center, retrospective observational cohort study which enrolled women with breast cancer
(BC) attending 8 participating cancer centers in Malaysia in 2011. All patients were followed up for 12 months from
diagnosis to determine their access to therapies. We assess care performance using measures developed by Quality
Oncology Practice Initiative, American Society of Clinical Oncology/National Comprehensive Cancer Network,
American College of Surgeons’ National Accreditation Program for Breast Centers as well as our local guideline.
Results: Seven hundred and fifty seven patients were included in the study; they represent about 20% of
incident BC in Malaysia. Performance results were mixed. Late presentation was 40%. Access to diagnostic and
breast surgery services were timely; the interval from presentation to tissue diagnosis was short (median = 9 days),
and all who needed surgery could receive it with only a short wait (median = 11 days). Performance of radiation,
chemo and hormonal therapy services showed that about 75 to 80% of patients could access these treatments timely,
and those who could not were because they sought alternative treatment or they refused treatment. Access to
Trastuzumab was limited to only 19% of eligible patients.
Conclusions: These performance results are probably acceptable for a middle income country though far below the
95% or higher adherence rates routinely reported by centres in developed countries. High cost trastuzumab was
inaccessible to this population without public funding support.
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Cancer is the leading cause of deaths and disability in
the world, and a widening disparity in cancer burden has
emerged between high income and low-middle income
countries (LMIC) [1,2]. Once thought to be exclusively a
burden for developed countries, developing countries
today bear an increasing proportion of the burden; In
1970, 15% of newly reported cancers were in developing
countries, compared with 56% in 2008 [3]. By 2030, the
proportion is expected to be 70% [3-5]. This is due to
population growth, ageing and changing lifestyles (smok-
ing, diet etc.). Developing countries also bear an increas-
ing share of the burden in cancer deaths; two-thirds of
the 7 · 6 million deaths every year from cancer world-
wide occur in LMIC [4,5]. This is due to improving sur-
vival in developed countries in the past 3 decades as a
result of earlier detection and new and more effective
treatments [6], but little of these advances are accessible
to most people in LMIC.
Closing this cancer divide between rich and poor
countries is not just an ethical imperative. There is
sound economic justification too for reducing avoidable
cancer deaths which are costly in economic productivity
terms. The Global Task Force on Expanded Access to
Cancer Care and Control in Developing Countries has
recently presented a compelling case for comprehensive
action on expanded access to cancer care and control
[1,2]. In responding to its call for action, we had
reviewed the cancer care services in Malaysia, a middle
income country, and it was immediately obvious there
was hardly any data at all to inform national cancer care
planning. Similarly there is little granularity to the per-
formance of cancer services in other developing coun-
tries too.
Evaluating the performance of cancer services however
is challenging. Unlike for HIV, with which cancer care is
often compared [7], where access could simply be mea-
sured by the number of HIV patients treated with anti-
retroviral drugs, there is no simple method for measuring
access to cancer care. Cancer care is far more complex
and multi-faceted. Early diagnosis is important, which re-
quires an active screening service and tissue diagnosis;
tumor characteristics are heterogeneous and there are
multiple treatment modalities which have to be individu-
ally tailored guided by specific tumor characteristics while
taking into consideration patient’s preference and local
availability of treatments. Cancer is increasingly a chronic
disease and its care could stretch over years, which further
complicates its measurement.
Fortunately, there have been recent advances in the
development of evidence based rigorous and scientific-
ally sound performance metrics [8-12]. These measures
basically recommend a specific treatment modality for a
sub-group of cancer patients defined by specific tumorcharacteristics, and further specify a time interval from
diagnosis when treatment should be initiated. These mea-
sures have been adopted by national bodies tasked with
healthcare quality oversight such as the National Quality
Forum in US [13]. This has helped standardize the collec-
tion of cancer care data and enable the evaluation of the
extent to which cancer care in a country adhere with
current evidence as described by the performance mea-
sures. It has also helped identify factors contributing to
sub-optimal care, so that appropriate strategies and inter-
ventions could be implemented to improve the delivery of
services.
We adopted these performance metrics to measure
performance of cancer care services in Malaysia, a mid-
dle income developing country in South East Asia with a
population of 28.9 million and GDP per capita of RM
30,420 (~USD9,000) in 2011 [14]. In 2012, Malaysia’s
age standardized cancer incidence was 143.6 per 100,000
population, cancer mortality 85.8 per 100,000 popula-
tion, giving a Mortality: Incidence ratio of 60% [15]. His-
torically, the Malaysian health care system, like other
former British colonies such as Hong Kong and Sri
Lanka in the region, has retained a tax-funded public
health service, much like the British National Health
Service, alongside a private sector in a mixed health
economy. However, as the economy matures, the pri-
vate health sector, largely financed by private insur-
ance, employer provided benefits or out-of-pocket
payment has become increasingly sizeable. In 2006, an-
nual health spending was 4.3% of GDP, of which public
and private finance accounted for 45% and 55% re-
spectively [16]. Finance and provision for cancer care
in Malaysia follow the same public-private split; the
public sector where patients receive publicly funded
therapy and the private sector where patients pay out
of pocket or their health insurance or employers fund
treatment.
Methods
We conducted a multi-center, retrospective observa-
tional cohort study to measure the performance of
breast cancer care services in Malaysia. A central ethics
committee, the Ministry of Health’s Medical and Re-
search Ethics Committee, has approved the study and
granted waiver from the requirement to obtain individ-
ual informed consent from patients. The waiver is justi-
fied by this being an observational study based entirely
on data abstracted from medical record, and that such
data are already routinely collected for healthcare quality
assurance purpose.
Study population
The study population consisted of women with breast
cancer diagnosed in year 2011. The 9 largest cancer
Table 1 Performance measures for evaluating breast
cancer care services in Malaysia
# Performance measure Source
Diagnostic services
Pathology report confirming malignancy QOPI [8,9]
Biomarker information QOPI [8,9]
Treatment services
Surgery for women under age 70 with
Stage I to III breast cancer within 60 days
of date of diagnosis
Malaysian guideline
[17]
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from both the public and private sector in Peninsular
Malaysia were invited to participate of which 8 agreed
to. Each centre was required to enroll all patients diag-
nosed and treated in the year 2011. Only Malaysian pa-
tients with primary breast carcinoma are included. Cases
are identified through hospital register as well as opera-
tive surgery, chemotherapy and radiotherapy records.
Case ascertainment for 3 of the centers was independ-
ently verified to be complete (100%).Adjuvant multi-agent (combination)
chemotherapy for women under age 70
with Stage I (T1c) to III ER/PR negative
breast cancer within 120 days of date
of diagnosis
ASCO-NCCN [10,11]
Radiation therapy for women under age
70 with Stage I to III breast cancer who
had breast conserving surgery for breast
cancer within 1 year (365 days) of date
of diagnosis
ASCO-NCCN [10,11]
Radiation therapy for women under age
70 who had mastectomy for breast cancer
with node + (four or more positive regional
lymph nodes) within 1 year (365 days) of
date of diagnosis
NAPBC [12]
Tamoxifen or Aromatase Inhibitor for
women greater than age 17 with Stage
I (T1c) to III ER or PR positive breast cancer
within 1 year (365 days) of date of diagnosis
ASCO-NCCN [10,11]
Trastuzumab therapy for women greater
than age 17 with Stage I (T1c) to III HER2
positive breast cancer within 1 year
(365 days) of date of diagnosis
QOPI [8,9]Study assessment and definitions
At enrollment, data were abstracted from patients’ med-
ical and histo-pathology (HPE) reports by trained data
collectors. Demographic data abstracted include age, sex
race and nationality; tumor characteristics include histo-
logic type, grade, location, extent, and size; lymph node
and distant organ metastases. Staging of disease was
based on the American Joint Committee on Cancer
(AJCC 7th Edition) criteria. AJCC stage I or II disease
were considered early breast cancer (EBC), stage III lo-
cally advanced BC (LABC) and stage IV metastatic BC
(MBC). After enrollment, all patients were followed up
for 12 months to collect data on their subsequent expos-
ure to cancer-directed therapies, which were abstracted
from medical, operative surgery, chemotherapy and radio-
therapy records.
For the purpose of measuring breast cancer care per-
formance, we adopted the performance measures (Table 1)
developed by Quality Oncology Practice Initiative (QOPI)
[8,9], American Society of Clinical Oncology/National
Comprehensive Cancer Network (ASCO-NCCN) [10,11],
American College of Surgeons’ National Accreditation
Program for Breast Centers (NAPBC) [12] as well as our
local clinical practice guideline [17].Independent data audit
A copy of the HPE report was retrieved for all patients
enrolled from all sites to verify tumor diagnosis and
characteristics. In addition, patients’ demographic and
treatment data from 3 sites were also subjected to inde-
pendent data verification against source documents on
site. The accuracy of the collected data with respect to
demographics, surgery, radiotherapy, chemotherapy, hor-
monal therapy and trastuzumab treatment were all >95%.Statistical methods
Continuous variables are described by summary statistics
such as mean, median, and standard deviation and cat-
egorical (nominal/ordinal) variables by the frequencies
of each category. The precision of the estimates is de-
scribed by 95% confidence interval (CI).Results
The 8 participating centres enrolled a total of 889 patients
in 2011. One hundred and thirty two patients were ex-
cluded because of incomplete data (121 patients for date
of diagnosis, 11 for tumor staging). Thus the final sample
size was 757 subjects, which represent about 20% of all in-
cident breast cancers in Malaysia in 2011.
Patients’ demographic and tumor characteristics
Table 2 shows the patients’ demographic and tumor
characteristics. The mean age of the women was only
53 years; about 40% was aged <50 years. 61% of patients
were diagnosed with Early Breast Cancer (Stage 1 or 2,
EBC), another 27% with Locally Advanced Cancer and
11% with late stage metastatic cancer. 65% were ER+,
57% PR+, 28% HER2+ and 12% triple negative.
Cancer care performance
Table 3 summarizes the performance results of Malaysian
cancer diagnostic services. For patients first presenting at
a treatment centre, it took a median of 9 days to arrive at
a diagnosis of cancer. All patients (100%) had a pathology
report confirming malignancy. One hundred and seventy







Age, years Mean (SD) 53(11)
Median (IQR) 53(46, 61)
(Min, Max) (23, 87)
Age distribution No. (%) age < 40 88(12)
No. (%) age 40 to 49 199(26)
No. (%) age 50 to 59 262(35)
No. (%) age > =60 208(27)
Sex No. (%) male 0(0)
No. (%) female 757(100)
Race No. (%) Malay 264(35)
No. (%) Chinese 377(50)
No. (%) Indian 95(13)
No. (%) Orang Asli 1(0)
No. (%) Bumiputera Sabah 0(0)
No. (%) others 20(3)
Stage at diagnosis* No. (%) Early Breast
Cancer (EBC)
463(61)
No. (%) Locally Advanced
Breast Cancer (LABC)
207(27)
No. (%) Metastatic Breast
Cancer (MBC)
87(11)
Tumor size* No (%) T1 (1 to 20 mm) 207(27)
No (%) T2 (21 to 50 mm) 246(32)
No (%) T3 (> 50 mm) 80(11)
No (%) unknown 224(30)
Regional node* No (%) negative node 206(27)
No (%) 1–3 positive node 117(15)
No (%) 4–10 positive node 75(10)
No (%) >10 positive node 49(6)
No (%) unknown 310(41)
Tumor histology* No (%) infiltrating duct
carcinoma, NOS
653(86)
No (%) intraductal carcinoma,
non-infiltrating, NOS
25(3)
No (%) other carcinomas 79(10)
Grading* No (%) grade 1 50(7)
No (%) grade 2 261(34)
No (%) grade 3 256(34)
No (%) no information 190(25)
Biomarkers No. (%) ER+ 494(65)
No. (%) missing information
on ER
37(5)
No. (%) PR+ 434(57)
No. (%) missing information on PR 40(5)
Table 2 Patient and tumor characteristics at diagnosis
(Continued)
No. (%) ER+/PR+ 516(68)
No. (%) missing information on ER & PR 36(5)
No. (%) HER2 ISH + or IHC + if ISH
missing or unknown
209(28)
No. (%) missing information on HER2 169(22)
No. (%) HER2 - 379(50)
No. (%) Triple positive (ER+, PR + HER+) 95(13)
No. (%) Triple negative (ER-, PR- HER-) 94(12)
No. (%) missing information ER, PR
and/or HER
173(23)
*Results on Staging and Histologic findings (tumor size, node, histology grade)
may not be consistent with one another because data on the former were
abstracted from patients’ medical records or treatment plan while latter were
abstracted from histo-pathology report submitted by participating sites.
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more tumor biomarkers (5% ER, 5% PR and 22% HER2).
Table 4 summarizes the performance results of Malaysian
cancer treatment services. Breast cancer surgery was
highly accessible; 671 (89%) patients had surgery with a
median time from diagnosis to surgery of only 11 days.
Only 25% of patients underwent breast conserving
surgery.
Performance for the 3 treatment modalities, radiation,
chemotherapy and hormonal therapy, were comparable.
Four hundred and seventy three (62%) patients had
chemotherapy with a median time from diagnosis to
treatment of 51 days. Most had an alkylating agents (95%),
anthracycline antibiotics (86%) or anti-metabolites (76%);
only 41% of patients had a taxane. 75% of patients eligible
for chemotherapy had care that adhere with the perform-
ance measure and received therapies within the prescribed
time.
Four hundred and sixty nine (62%) patients had radio-
therapy with a median time from diagnosis to treatment
of 194 days. Half of them had whole breast external ir-
radiation while 38% had tumour bed (boost) irradiation.Table 3 Performance of cancer diagnostic services for a
breast cancer cohort in Malaysia, in year 2011
# Performance of cancer diagnostic services N = 757
1. Median (IQR) duration from first presentation
at site to diagnosis, days
9(4, 9)
2. Number (%) of patients with Pathology report
confirming malignancy
757(100)
3. Number (%) of patients with information on ER 720(95)
4. Number (%) of patients with information on PR 717(95)
5. Number (%) of patients with information on HER2 588(78)
6. Number (%) of patients without information on
ER or PR or HER2
173(23)
Table 4 Performance of cancer treatment services for a breast cancer cohort in Malaysia in year 2011
# Performance measures for cancer treatment
services
Number of patients eligible







95% CI of percent of
patients whose care adhere
with performance measure
1. Patients under age 70 with Stage I to III Breast
cancer who received Surgery within 2 months of
diagnosis
610 82% (79, 85)
2. Patients under age 70 with Stage I (T1c) to III ER/PR
negative Breast cancer who received
Chemotherapy within 4 months of diagnosis
171 75% (68, 81)
3. Patients under age 70 with Stage I to III Breast
cancer who received Radiation therapy after breast
conserving surgery within 1 year of diagnosis
159 77% (69, 83)
4. Patients under age 70 Node + Breast cancer who
received Radiation therapy after mastectomy within
1 year of diagnosis
89 81% (71, 88)
5. Patients under age 70 with Stage I (T1c) to III ER or
PR positive Breast cancer who received Tamoxifen
or AI within 1 year of diagnosis
428 76% (72, 80)
6. Patients under age 70 with Stage I (T1c) to III HER2
positive Breast cancer who received Trastuzumab
within 1 year of diagnosis
172 19% (14, 26)
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conserving surgery within the prescribed time, while
81% who had radiotherapy after mastectomy had care
that adhered with the performance measure. Four hun-
dred and thirty (57%) patients had hormonal therapy
with a median time from diagnosis to treatment of
171 days. Most had tamoxifen (85%), only 13% of pa-
tients had an aromatase inhibitor. And 76% of eligible
patients had care that adhered with the performance
measure. For a subset of these patients (N = 89) whose
care did not adhere with the performance measures, fur-
ther investigations showed the common reasons for
non- adherence were the patients having sought care in
another centre (33%), sought alternative or traditional
treatment (16%) or they had refused treatment (50%).
For patients with HER2 positive cancer, access to tar-
geted therapy (trastuzumab) was very limited; only 19%
of eligible patients could be treated.Discussion and conclusion
Breast cancer is a common disease across the world but
outcomes vary significantly between high and low income
countries. Most women diagnosed with breast cancer in
high-income countries can reasonably expect to be cured
and enjoy a long life expectancy. Such progress has been
made possible by screening programmes that enable early
detection and by the use of multiple modality treatments.
However, in low and middle income countries, under-
resourced and under-performing health services continue
to fail to deliver adequate screening and treatments lead-
ing to poor outcomes for patients with breast cancer.In the year 2011, we measure the performance of
breast cancer care to inform our advocacy for better
cancer services in Malaysia. The study sample is large
(20% of incident cases in 2011) but it is not likely to be
representative of the population it aims to describe. The
cancer care performance results presented here are likely
to be better than they really were (optimistic bias).
Firstly, patients were enrolled from 8 of the 9 leading
cancer centers in Peninsular Malaysia where cancer spe-
cialist manpower and physical infrastructure are concen-
trated. Clearly large number of BC patients in Malaysia
received care in less well-resourced settings and they are
not included in this study. Secondly, only patients with
complete data can be included in the performance meas-
ure analysis. For example, for the measure “Patients
under age 70 with Stage I to III ER/PR negative Breast
cancer who received Chemotherapy within 4 months of
diagnosis”, to be included in this analysis require a pa-
tient to have complete data (non-missing) on date of
diagnosis and date treatment was started, details on sta-
ging (T1c or Stage II or III), ER and PR, age (18–
69 years) and treatment course (only the first is
counted). However as shown in Table 2, critical data to
inform clinical decision making were frequently missing
(30% for tumor size, 22% for HER2 etc.) in the real
world practice in developing countries. In so far that pa-
tients with more complete information are likely to re-
ceive better care, the results are optimistically biased.
Thus, the cancer care performance results presented
here represent the upper bound of what is achievable in
a middle income country. The results however are un-
likely to be affected by selection bias due to selective
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centres. Similarly selective reporting is also unlikely as
an independent audit has verified the accuracy of the
data. The estimate of non-adherence with performance
measure does not take into account individual physician
practice style or patient preference; the performance mea-
sures were designed to ignore such considerations [10].
The performance results were mixed. Late presenta-
tion was 40% which is the same as more than 10 years
ago when this was first reported [18,19], indicating little
progress at all in cancer screening services in the past
10 years, notwithstanding stage shift due to changes in
AJCC definition over the years. On the positive side, we
found timely access to diagnostic and breast surgery ser-
vices. The interval from presentation to tissue diagnosis
was short, and all who needed surgery could receive it
with only a short wait. Performance of radiation, chemo-
therapy and hormonal therapy services were probably
acceptable. About 75 to 80% of patients could access
these treatments in a timely fashion, and those who
could not were because they sought alternative treat-
ment or treatment elsewhere, or they simply refused
treatment. These performance results are probably cred-
itable for a middle income country though obviously
they are far below the 95% or higher adherence rates
routinely reported by many centres of excellence in de-
veloped countries [20-23]. Access to trastuzumab was
the only problematic area in Malaysian cancer care. This
was entirely due to the high cost and inadequate public
funding for the treatment.
The results presented here merely describe the mean
performance of the cancer care provided by 8 leading
centers in Malaysia, 2 of these centres are publicly
owned. We did not address the likely variation in cancer
care performance between centres or between public
and privately owned centres for several reasons. The
study protocol explicitly prohibits comparative perform-
ance analysis between centres. This was necessary to at-
tract centers to voluntarily contribute data to this study
mostly at their own expense. Besides the sensitivity of
comparative performance analysis, defining whether a pa-
tient is private or public is not straightforward in a highly
fragmented cancer care system, such as the one in
Malaysia. The boundary between centers are ill-defined
and porous. One of the public centre in our sample also
treat fees paying patients within the same centre alongside
public patients. Another public hospital in the sample rou-
tinely outsource radiotherapy services to private centres.
Oncologists in public hospitals commonly (probably al-
most all of them) practice privately and many of their pri-
vate patients see them in their public practice too and vice
versa. And finally in the course of their cancer care, all pa-
tients frequently move between centres whether within
the public or private sector or between the 2 sectors.A high performing health service is crucial to translat-
ing medical advances into improved health for the popu-
lation. To our knowledge, this is the first time cancer
service in a developing country has been subjected to
measurement using standardized performance metrics.
Clearly there is room for improvement. The results are
useful too as a baseline against which future improve-
ment will be measured. The results also highlight the
importance of routine performance measurement in
healthcare, which is under-developed in many develop-
ing countries despite their high cancer burden [24]. In-
vestment in health without monitoring the return on the
investment and without holding the recipients of health
funding and providers of healthcare accountable would
be unconscionable [25].
Many strategies and solutions have been proposed to
improve cancer services in developing countries [1,26,27].
First, the fragmented cancer services typically found in
many middle-income countries including Malaysia need
to be reformed; we should explore novel models of care
delivery [28,29]. Second, the innovative financing, pricing
and procurement strategies which had successfully aided
the fight against communicable diseases such as HIV/
AIDS, could similarly be employed in cancer care to im-
prove access to high cost medicines. The pharmaceutical
industry has been responsive to the needs of developing
countries by offering “access schemes” [7] or second brand
product [30] which substantially reduce prices and render
the treatment more accessible. Ultimately, leadership and
advocacy for cancer care needs to be strengthened. Cancer
service in Malaysia as described in this study has much to
learn yet from other high cost services such as dialysis.
Able leadership and the will to radically reform the finan-
cing and delivery of dialysis service informed by rigorous
health policy research were crucial to achieving universal
access to dialysis in Malaysia [31]. We need to do the
same for cancer care.
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